Last reviewed · How we verify
A-101 Solution 40
A-101 Solution 40 is a topical solution used to treat hyperhidrosis.
A-101 Solution 40 is a topical solution used to treat hyperhidrosis. Used for Treatment of primary axillary hyperhidrosis.
At a glance
| Generic name | A-101 Solution 40 |
|---|---|
| Sponsor | Aclaris Therapeutics, Inc. |
| Drug class | anticholinergic |
| Target | muscarinic receptors |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the sympathetic nervous system's ability to stimulate sweat glands, thereby reducing excessive sweating. The exact molecular target is not well-documented, but it is believed to involve the inhibition of acetylcholine release or its action on muscarinic receptors.
Approved indications
- Treatment of primary axillary hyperhidrosis
Common side effects
- dry skin
- itching
- redness
Key clinical trials
- Study of A-101 for the Treatment of Seborrheic Keratosis (PHASE2)
- A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra (PHASE2)
- An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses (PHASE4)
- Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis (PHASE2)
- Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis (PHASE1, PHASE2)
- A Study of A-101 Solution in Subjects With Common Warts. (PHASE2)
- An Open-Label Safety Study of A-101 Solution (PHASE3)
- A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A-101 Solution 40 CI brief — competitive landscape report
- A-101 Solution 40 updates RSS · CI watch RSS
- Aclaris Therapeutics, Inc. portfolio CI